The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med1987; 316:1429-35.
2.
The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991;325:293-302.
3.
Garg R., Yusuf S.Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE Inhibitor Trials. JAMA1995;273:1450-6.
4.
Packer M., Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation1999;341:709-17.
5.
Pitt B., Zannad F., Remme WJ et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study. NEnglJMed1999;100:2312-8.
6.
Pitt B., Chang P., Timmermans PBM.Angiotensin-II receptor antagonists in heart failure - Rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovascular Drugs and Therapy1995;9:693-700.
7.
Pitt B., Segal R., Martinez FA, Meurers G., Cowley AJ, Thomas I. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet1997;349:747-52.
8.
Pitt B., Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail1999;5:146-54.
9.
Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -- the Losartan Heart Failure Survival Study ELITE II. Lancet2000;355:1582-7.
10.
Tsuyuki RT, Yusuf S., Rouleau JL et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Card1997;13:1166-74.
11.
McKelvie RS ,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation1999 ;100:1056-64.
12.
Cohn JN, Tognoni G., Glazer RD, Spormann D., Hester A.Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail1999;5:155-60.
13.
Wolny A., Clozel JP, Rein J. et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circulation Research1997 ;80:219-27.
14.
Voors AA, Pinto YM, Buikema H. et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol1998;125:1028-32.
15.
Petrie MC, Padmanabhan N., McDonald JE, Hillier C., Connell JMC, McMurray JJV.Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol2001;37:1056-61.
16.
Siragy HM, Carey RMAngiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens2001 ;1:99-103.
17.
Berry C., Norrie J.,McMurray J.Are Angiotensin II receptor blockers more efficacious than placebo in heart failure? implications of ELITE-2. Am J Cardiol2001;87:606-7.
18.
Horton R.From star signs to trial guidelines. Lancet2000; 55:1033-4.
19.
Pfeffer MA, McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial - VALIANT: rationale and design. Am Heart J2000;140:727-50.
20.
Swedberg K. , Pfeffer M., Granger C. et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail1999;3:5276-82.
